Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief

This article was originally published in The Pink Sheet Daily

Executive Summary

Boehringer Ingelheim submits type 2 diabetes therapy empagliflozin; Pozen seeks a partner to help it commercialize its aspirin/PPI combo following its NDA submission; Eisai gets FDA approval for pediatric use of acid reflux drug Aciphex; Merck announces FDA’s acceptance of its oral grass pollen allergy immunotherapy BLA; the EMA accepts Shionogi’s menopause drug Osphena for review, and IntelGenx submits an NDA for an oral film version of Maxalt-MLT.


Related Content

Faldaprevir And Simeprevir Outshine Today’s Protease Inhibitors
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana
Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon
Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts